Cat's Claw — Research Profile

Uncaria tomentosa exists in two chemotypes: pentacyclic oxindole alkaloid (POA) and tetracyclic oxindole alkaloid (TOA). POAs are anti-inflammatory and immunomodulating. TOAs may antagonize POA activity. Quality supplements should be standardized to POAs with low or no TOA content. The POA chemotype was used in the pivotal RA trial showing significant joint pain reduction ^[1].

Cat's claw has immune-modulating (not purely immune-stimulating) properties. The RA trial by Mur et al. showed benefits alongside conventional therapy. However, due to its immune effects, anyone with autoimmune conditions should use it only under medical supervision.

The OA trial by Piscoya et al. showed pain relief within 1 week. For RA, the Mur et al. trial reported significant improvements by week 24, with some benefits appearing earlier. Allow at least 4-8 weeks for chronic inflammatory conditions.

All human evidence used oral preparations: a purified pentacyclic (POA) chemotype extract for rheumatoid arthritis, a freeze-dried whole extract of Uncaria guianensis for knee osteoarthritis, and a water-soluble extract (C-Med-100, 700 mg/day) for immune endpoints. No head-to-head trial establishes one form as superior, but an oral capsule or tablet of a POA-standardized Uncaria tomentosa extract most closely matches the arthritis trial material.

The strongest human evidence is for joint symptoms. A 24-week randomized trial of the pentacyclic (POA) chemotype extract in rheumatoid arthritis reduced the number of painful joints by 53.2% versus 24.1% for placebo (p=0.044). A 4-week trial of freeze-dried Uncaria guianensis reduced knee-osteoarthritis pain with activity, with improvement in the first week. NCCIH cautions there is no conclusive human evidence for other promoted uses such as cancer, viral infections, or COVID-19.

No official dose is established. LiverTox reports usual doses range from 30 to 300 mg of extract once daily. The rheumatoid arthritis trial used 60 mg/day of the pentacyclic (POA) chemotype extract, given as 20 mg three times daily (the standardized Krallendorn preparation), while the immune study used 700 mg/day of a water-soluble extract. Because potency and standardization differ widely by preparation, follow the specific product's labeled extract dose rather than a single universal figure.

Time of day has not been tested; LiverTox notes cat's claw is typically taken once daily, and the trials did not specify morning versus evening dosing. Taking it with food is a reasonable way to reduce the nausea and gastrointestinal upset that are its main reported side effects.

LiverTox lists nausea, gastrointestinal upset, and diarrhea as the minor side effects, describing cat's claw as well tolerated with no serious adverse events and no changes in serum ALT or AST in trials. The rheumatoid arthritis trial similarly reported only minor side effects over its 52 weeks. NCCIH adds that cat's claw may stimulate the immune system, which could worsen autoimmune disease, and may slow blood clotting.

Yes. LiverTox notes cat's claw inhibits CYP3A4, so it can raise blood levels of drugs metabolized by that enzyme, and it interacts particularly with anticoagulants. NCCIH adds theoretical interactions with antiplatelet and blood-pressure medications and advises caution around surgery because cat's claw may slow blood clotting.

The best trial support is in adults seeking adjunct symptom relief for rheumatoid arthritis or knee osteoarthritis. It is contraindicated in pregnancy and breastfeeding and in organ-transplant recipients, per LiverTox. NCCIH advises people with autoimmune disease, those taking anticoagulant or antiplatelet drugs, and anyone scheduled for surgery to avoid it, because it can stimulate the immune system and slow blood clotting.

Onset depends on the target. In a knee-osteoarthritis trial, pain with activity improved within the first week of treatment, though rest and night pain did not change over the 4-week study. In the rheumatoid arthritis trial using the pentacyclic (POA) chemotype extract, joint-pain reduction was measured across a 24-week phase, so meaningful arthritis benefit was assessed over months rather than days. Onset has not been directly compared across products or conditions.

NCCIH states oral cat's claw appears safe when used for short periods, up to about 6 months. The rheumatoid arthritis trial dosed the pentacyclic-chemotype extract for 52 weeks with only minor side effects, and LiverTox rates it an unlikely cause of liver injury (likelihood score E) with no changes in serum ALT or AST in trials. Safety much beyond a year has not been established.

No toxic threshold or upper limit has been established. LiverTox reports usual doses range from 30 to 300 mg of extract once daily, and an immune study gave 700 mg/day of a water-soluble extract for two months with no toxic effects on medical exam, clinical chemistry, or blood counts. Excess intake most likely causes gastrointestinal upset; because cat's claw inhibits CYP3A4 and may slow blood clotting, higher intake raises drug-interaction and bleeding concerns rather than direct organ toxicity.

No specific supplement combination has been shown to improve results for POA-standardized cat's claw. Use caution with other supplements that affect clotting, such as fish oil, ginkgo, or vitamin E, because NCCIH notes cat's claw may slow blood clotting and could add to bleeding risk. Its CYP3A4 inhibition can also raise blood levels of other botanicals metabolized by that enzyme.

Confirm the species is Uncaria tomentosa and that the product is standardized to pentacyclic oxindole alkaloids (POAs), the chemotype used in the rheumatoid arthritis trial; some products instead use Uncaria guianensis, which was the OA-knee study material. Reputable POA-standardized extracts are screened to minimize tetracyclic oxindole alkaloids (TOAs), though human trials directly comparing standardized versus unstandardized products are lacking, so standardization is a manufacturing rationale rather than a proven efficacy advantage. Look for third-party purity/identity testing.